Company / Shareholders' Equity
NewAmsterdam Pharma Co N.V. Shareholders' Equity History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$683.4M
FY2025
5-year range
-$113.8M / $757.5M
FY2021-FY2025
Trend
-9.8%
vs FY2024
Sector context
#69 of 214
Health Care
What the data says
At $683M, NewAmsterdam Pharma Co N.V.'s shareholders' equity ranks #69 of 214 in the Health Care sector. Shareholders' Equity has fluctuated over the past 5 years, ranging from -$114M in FY2021 to $758M in FY2024.
Based on SEC 10-K filings.
$683M in FY2025 with a 3-year CAGR of +16.7%.
Improved from $288M to $683M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +16.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#69 of 214 in Health CareTop 32% of 214This company $683.4M Sector average $2.6B
▼
-73.4% below sector average
Key checks
Key Insights
- 3-year CAGR of +16.7%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 9.8% year-over-year.
- Ranks #69 out of 214 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.01 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $683.4M | -9.8% |
| FY2024 | $757.5M | +162.7% |
| FY2023 | $288.4M | -32.9% |
| FY2022 | $430.1M | +477.9% |
| FY2021 | -$113.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026